Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, disputes the use of ibrutinib in small subgroups vs all patients with chronic lymphocytic leukemia (CLL). Prof. Cymbalista contends that due to the potential toxicities, the indication of chemo-immunotherapy should be narrowed to patients with mutated IGHV. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).